Stocks in news today: Indiabulls Housing, Axis Bank, United Breweries, NTPC, United Breweries, Biocon and more
A Biocon spokesperson said the company is confident of addressing the observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA)
Speaking at a press conference today, they said the synergistic future oriented deal will help growth of both companies
On September 16, Sensex closed above the 59,000 mark for the first time, led by gains in banking stocks. Nifty too ended above 17,600 level, with 28 of 50 components ending in the green.
The alliance will also develop antibodies in order to target diseases such as dengue, HIV etc. Both companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of these vaccines and antibodies
Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was at Rs 1,712.1 crore for the same period a year ago.
Senior vice president of Biocon, Shreehas P Tambe, being an insider traded in the shares of the firm between December 19-27, 2017, in violation of market norms
Syngene, majority owned by biopharmaceutical company Biocon Ltd, is one of the seven Indian companies that have licensed remdesivir from U.S.-based Gilead Sciences Inc
Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh for trading in the company's securities when the trading window was closed
Kiran Mazumdar-Shaw, Executive Chairman, Biocon said the Indian government placed orders for vaccines very late in April which was now causing a shortage and chaos. In a conversation with India Today, Shaw said that the government should have initiated the order request for the required vaccines at the start of the year itself. The Biocon Chief added that the problem lay with the Logistics and planning processes, a weakness of the Indian government. Watch as she explains how decentralisation was necessary and how states must have the freedom for dealing with the vaccination process.
Biocon Executive Chairman Kiran Mazumdar-Shaw has expressed concern over the shortage of COVID-19 vaccines and sought better transparency from the government regarding their availability so that citizens could patiently wait for their turn. "Can we please know where the 70 million doses are being deployed every month? We need better transparency to avoid suspense. If a timetable of supplies is made public people can patiently wait their turn", said Shaw in a tweet on Tuesday while tagging the Health Ministry. Earlier this month, the Health Ministry had noted that a 100 per cent advance of Rs 1,732.50 crore was released to the Serum Institute of India (SII) on April 28 for 11 crore doses of Covishield vaccine. The ministry had also stated that against the last order of 10 crore doses for supplies of Covishield vaccine, 8.744 crore doses had been delivered till May 3. Watch the video for more.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today